Clinical Trial Update: Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) [Phase 2]

View source ↗

Summary

Phase 2 TRIGGER-PCI evaluated platelet reactivity testing to guide switching from clopidogrel to prasugrel in elective stent patients; the trial was terminated,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)
• PRASUGREL (prasugrel)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Coronary Artery Disease (CAD) | Phase 2 | Status: TERMINATED | Results posted: 2012-06-08